1	Colchicine for Prevention of Major Adverse Cardiovascular Events
2	A systematic review and meta-analysis of randomized clinical trials
3	
4	Federico Ballacci, MD ^{1*} , Federica Giordano, MD ^{1*} , Cristina Conte, MD ¹ , Alessandro Telesca, MD ¹ ,
5	Valentino Collini, MD ¹ , Massimo Imazio, MD, FESC ^{1,2} .
6	
7	1. Cardiothoracic Department, University Hospital Santa Maria della Misericordia, Udine, and
8	Department of Medicine, University of Udine.
9	2. Department of Medicine, University of Udine, Udine, Italy
10	
11	*These authors have contributed equally as first authors of the paper
12	
13	Correspondence to:
14	Prof. Massimo Imazio, MD, FESC. Cardiothoracic Department, University Hospital Santa Maria
15	della Misericordia, Udine, and Department of Medicine, University of Udine.
16	E-mail massimo.imazio@uniud.it

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 Abstract

Aims. Inflammation is a main pathophysiological driver in atherosclerotic cardiovascular diseases
 (ASCVD). Low-dose long-term colchicine for secondary prevention in patients with established
 ASCVD has been studied in multiple randomized trials in the last decade.

36 This meta-analysis aimed to evaluate the efficacy and safety of long-term low-dose colchicine for

37 secondary prevention in patients with established ASCVD.

Methods. We conducted a systematic review and meta-analysis following PRISMA guidelines to evaluate studies reporting long-term outcomes in patients with ASCVD. We systematically searched PubMed, EMBASE and Scopus databases for relevant studies up to December 1, 2024. The primary outcome was the occurrence of Major Adverse Cardiovascular Events (MACE), a composite of cardiovascular death (CVD), myocardial infarction (MI) and stroke. Random-effects models were used to calculate pooled risk ratios (RR).

Results. Ten randomized clinical trials enrolling 22532 patients were identified. Addition of colchicine to standard medical treatment in patients with established ASCVD reduced the risk for MACE by 27% (RR 0.73, 95% CI 0.57 – 0.95), with a number needed to treat of 52. Colchicine was found to significantly reduce the risk of myocardial infarction (RR 0.83, 95% CI 0.72 - 0.96) and coronary revascularization (RR 0.79, 95% CI 0.65 - 0.94). There were no significant differences between the two groups concerning cardiovascular and non-cardiovascular mortality, risk of serious gastrointestinal events, infections requiring hospitalization and cancer.

51 Conclusions. These findings support the use of long-term low-dose colchicine for secondary
52 prevention of MACE in clinical practice.

Introduction 53

54 Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide, with a rising global burden despite advances in prevention and treatment strategies. 55

Current guidelines strongly emphasize secondary prevention measures after coronary artery disease 56 or stroke diagnosis, including lifestyle interventions, risk factor control, and antithrombotic 57 therapy.[1,2] However, a significant residual risk of major adverse cardiovascular events (MACE) 58 59 persists even with optimal treatment adherence.[3,4]

Inflammation is a key pathophysiological driver of atherosclerosis, with the potential to be an 60 actionable target, as suggested by the association between inflammatory biomarkers, anti-61 62 inflammatory therapy and cardiovascular outcomes.[5–8] Colchicine, a potent and widely available anti-inflammatory agent extracted from plants of the genus Colchicum, has been widely used in the 63 treatment of inflammatory diseases such as gout, familial Mediterranean fever, and pericarditis with 64 65 good efficacy and safety profiles.[9–15] Its anti-inflammatory effects involve multiple pathways, including inhibition of microtubule formation and neutrophil function (i.e. chemotaxis, adhesion and 66 mobilization), as well as inhibition of NLRP3 inflammasome.[16] 67

Early landmark studies, such as the COLCOT and the LoDoCo2 trials, demonstrated that colchicine 68 reduces cardiovascular events in coronary artery disease.[17-20] However, these initial results have 69 70 been challenged by subsequent trials, including CONVINCE in stroke patients[21] and CLEAR in post-myocardial infarction patients, [22] which have shown neutral results. To address these 71 uncertainties, we conducted a systematic review and meta-analysis of randomized clinical trials to 72 73 assess the overall effect of colchicine on major adverse cardiovascular events and their individual components in patients with coronary disease, recent myocardial infarction, and stroke. 74

75 Methods

This study was performed in accordance with the Preferred Reporting Items for Systematic Reviews
and Meta-analysis (PRISMA) Guidelines.[23] The study protocol and the analysis plan were
developed prospectively, and are available on the Open Science Framework (https://osf.io/dqgwj).

79 Search strategy

A comprehensive search for relevant articles on PubMed, EMBASE and Scopus was performed from
 inception through December 1st, 2024.

The search strategy combined the term "colchicine" with cardiovascular-related terms including 82 "atherosclerosis", "coronary artery disease", "coronary heart disease", "angina", "infarction", 83 84 "coronary syndrome", "ACS", "ischemic heart disease", "percutaneous coronary intervention", "PCI", "myocardial ischemia" and "stroke", with appropriate adaptations to each database. Only full-text 85 publications were considered eligible, while conference abstracts were excluded. No other exclusion 86 87 criterion was used. Reference lists of included articles were screened to identify further relevant 88 studies. For trials with multiple published reports, the report with the longest pre-specified follow-up was selected, provided that blinding integrity was maintained. 89

90 Selection criteria

91 Studies were considered eligible if they were randomized clinical trials enrolling adult participants 92 with established ASCVD, with the intervention consisting of long-term colchicine treatment (>3 93 months) compared to standard treatment. Studies were not considered eligible if they did not report 94 outcomes for cardiovascular death or myocardial infarction. Reviews and case reports were excluded.

95 Complete inclusion and exclusion criteria can be found in the **Supplemental Material**.

96

Data extraction and quality assessment

97 Two investigators (FB and FG) independently reviewed the titles, abstracts, and full texts for inclusion 98 criteria. Conflicts between reviewers were resolved by consensus or by consultation with a third 99 investigator (MI). The following data were extracted from the included articles: first author or trial 100 name, publication year, patient characteristics, intervention and follow-up duration. Risk of bias was

independently assessed by two investigators (FB and FG) according to the Cochrane Collaboration 101 102 revised risk-of-bias tool for randomized trial (Rob2 version 2.0) composed of five domains: randomization process (D1); deviations from intended interventions (D2); missing 103 out-104 (D3); the (D4); selection come data measurement of outcome and of the 105 reported result (D5).[24,25]

106 *Outcome definition*

107 The primary endpoint was defined as the composite of myocardial infarction, stroke, and 108 cardiovascular death (MACE). Secondary endpoints included the composite of myocardial infarction, 109 stroke, cardiovascular death, and coronary revascularization, as well as each of these components 110 analysed individually.

Safety outcomes that were consistently reported across the included studies were also evaluated (noncardiovascular death, serious infections, pneumonia requiring hospitalization, serious adverse gastrointestinal events, cancer).

114 Statistical Analysis

We used a random-effects model with the Paule-Mandel estimator to calculate the pooled risk ratios (RR) with 95% confidence intervals (CIs) for the primary and secondary outcomes. A fixed-effects model was also conducted as sensitivity analysis. Heterogeneity was assessed using the I² statistic, Galbraith plots were evaluated to identify outliers when I² exceeded 50%.

A pre-specified subgroup analysis was performed for studies exclusively enrolling patients with acute coronary syndromes (ACS). Meta-regression analyses were restricted to studies with complete covariate data, and were used to explore the relationship between treatment effects and study-level characteristics including the proportion of ACS patients, diabetes, female sex, statin use, active smoking, and beta-blocker therapy. Leave-one-out sensitivity analyses were performed to assess the robustness of the findings. Publication bias was evaluated by examination of funnel plots. All statistical analyses followed the intention-to-treat principle. Statistical significance was set at p < 0.05

(two-tailed). All analyses were performed using R version 4.3.3 (R Foundation for Statistical
Computing, Vienna, Austria) with the *meta* and *metafor* packages.

128

129 Results

130 Search Results and Baseline Characteristics

The literature search identified a total of 5982 titles. After duplicate removal, titles and abstracts of 3284 papers were evaluated, and 43 articles were considered for full-text screening. Of these, 10 studies met the inclusion criteria and were included in the meta-analysis.[17,18,21,22,26–31] The references of all the included studies were searched for eligible entries, and no other study was deemed eligible for inclusion. The PRISMA flow diagram and checklist are shown in **Supplementary**

Table S1 and Figure S1.

Seven studies were rated as being at "low" risk of bias, 1 study was rated as being at "high" risk of
bias,[27] while 2 studies had unclear risk of bias[22,31] (Supplementary Figure S2).

A total of 22532 patients (female 4574, 20.3%) from 10 randomized clinical trials were included in the analysis. Trial inclusion criteria and comprehensive data are reported in **Table 1** and **Table 2**. In three trials, patients in the control group received optimal medical therapy without administration of placebo.[18,21,27] Differently from the other trials which included patients affected by coronary syndromes, one trial included patients affected by stroke as the main inclusion criterion.[21] Among coronary syndrome trials, 13,154 patients had ACS as a qualifying event, while 6,189 patients were affected by stable coronary artery disease.

Median duration of follow-up ranged from a minimum of 6 months to a maximum of 36 months. In 6 trials, colchicine was administered at a dosage of 0.5 mg once daily,[17,21,26–28,30] while it was administered twice daily by Deftereos et al.[31] To ascertain treatment tolerance, investigators of the LoDoCo2 trial employed an open-label 30-day run-in phase before blinding and proceeding to the administration of 0.5 mg daily.[18] Patients enrolled in COPS the trial would receive colchicine 1 mg daily for the first month, followed by 0.5 mg once daily for 11 months.[29] The protocol of the

152 CLEAR trial was changed due to higher-than-expected discontinuation rates, and the administered153 dosage was changed to 0.5 mg per day. [22]

- Results of the COPS trial for the composite of MACE and coronary revascularization, as well as cardiovascular and non-cardiovascular death, are reported according to the two-year follow-up prespecified analysis. [29,32]
- 157 *Composite of Cardiovascular Death, Myocardial Infarction and Stroke*
- 158 Seven studies reported data on the primary outcome of this meta-analysis.[17,18,21,22,26,28,30] A
- total of 1428 (6.5%) patients developed MACE. The pooled analysis showed that colchicine reduced
- 160 the RR for MACE by 27% [95% confidence interval (CI) 0.57 0.95, $I^2 = 58\%$] (Figure 1, Figure
- 161 2). Results were consistent for all studies at leave-one-out analysis. The estimated number needed to
- treat to prevent one occurrence of MACE was 52.
- At Galbraith plot analysis, three trials were identified as the main outliers, with CLEAR[22] showing
 a neutral effect of colchicine, while LoDoCo[30] and Akrami et al.[28] showed a RR of 0.43 and
- 165 0.32, respectively. Funnel plot inspection did not show clear publication bias, suggesting only mild
- asymmetry in small studies (Supplementary Figure S3).
- 167 Meta regression showed that active smoking significantly affected the effect of colchicine ($\beta = 1.10$,
- 168 95% CI 0.21 1.99, p = 0.016), with a greater treatment effect observed in populations with lower 169 smoking rates. Other covariates did not affect the treatment effect.
- Subgroup analysis of trials enrolling ACS vs CCS patients showed a neutral effect of colchicine (RR 0.73, 95% CI 0.47 1.14) in the ACS group, but there were no significant differences with the CCS
- 172 group (p = 0.60).
- 173 Secondary outcomes

174 Colchicine reduced the relative risk of the composite of MACE and coronary revascularization by 175 26% (RR 0.74, 95% CI 0.60 - 0.91, $I^2 = 71\%$). Heterogeneity was mainly driven by CLEAR[22] 176 showing neutral results (RR 0.99, 95% CI 0.85 - 1.14), while COLCOT and LoDoCo showed a RR

0.77 and 0.71, respectively.[17,30] Among individual components (Figure 1, Figure 3), colchicine 177 significantly reduced the risk of myocardial infarction (RR 0.83, 95% CI 0.72 - 0.96, $I^2 = 0\%$) and 178 coronary revascularization (RR 0.79, 95% CI 0.65 - 0.94, $I^2 = 30\%$). A trend towards stroke reduction 179 was observed but did not reach statistical significance (RR 0.73, 95% CI 0.50 - 1.06). Cardiovascular 180 mortality was similar between groups (RR 0.97, 95% CI 0.79 - 1.19; Figure 4). Results for individual 181 endpoints were relatively homogeneous across all trials ($I^2 < 50\%$). Funnel plot inspection did not 182 show clear publication bias, suggesting only mild asymmetry in small studies (Supplementary 183 Figure S3). Meta-regression analyses did not identify any significant effect modifiers for these 184 outcomes. The estimated number needed to treat to avoid one occurrence of myocardial infarction or 185 186 unplanned coronary revascularization were 168 and 92, respectively. Subgroup analysis of trials enrolling ACS vs CCS patients showed a neutral effect of colchicine on all secondary outcomes in 187 the ACS group, but there were no significant differences with the CCS group. 188

189 *Safety Outcomes*

190 Colchicine therapy did not increase the risk of non-cardiovascular mortality (RR 1.07, 95% CI 0.80 - 1.42, $I^2 = 46\%$; Figure 4). The risk of serious infections was similar between groups (RR 0.99, 95%) 191 CI 0.79 - 1.25, $I^2 = 36$ %). Serious gastrointestinal adverse events showed a slight numerical increase 192 with colchicine, although not reaching statistical significance (RR 1.13, 95% CI 0.92 - 1.39, $I^2 = 0\%$). 193 194 For pneumonia requiring hospitalization, while the pooled estimate showed no significant difference (RR 1.33, 95% CI 0.60 - 2.95), there was substantial heterogeneity across trials ($I^2 = 64\%$), with 195 COLCOT[17] showing an increased risk (RR 2.35, 95% CI 1.08 - 5.11) not confirmed in other studies. 196 Importantly, cancer incidence was similar between groups (RR 0.97, 95% CI 0.82 - 1.15, $I^2 = 0\%$). 197 Forest plots for these safety outcomes are shown in Supplementary Figure S4. 198

199

200 Discussion

This study-level meta-analysis of ten randomized clinical trials enrolling 22532 patients with ASCVD provides evidence that long-term low-dose colchicine is effective in reducing the risk of MACE, myocardial infarction and unplanned coronary revascularization in patients with ASCVD.

Previous meta-analyses have shown a protective effect of colchicine when compared to placebo or standard of treatment in regard to MACE, stroke, myocardial infarction and coronary revascularization.[33,34]

The recent publication of CLEAR,[22] the largest trial on long-term colchicine therapy in patients with ASCVD, challenged these findings showing an overall neutral effect of colchicine in acute coronary syndromes on the primary outcome of MACE.

To the best of our knowledge, this meta-analysis is the first to pool the effect of the CLEAR trial with other landmark trials on long-term low-dose colchicine in ASCVD. Regarding the primary endpoint (MACE), CLEAR[22] was the one with the highest relative weight among the included studies (32.0%, followed by CONVINCE[21] and LoDoCo2[18] with 22.6% and 20.1%, respectively). Nonetheless, this meta-analysis demonstrates a significant 27% relative risk reduction in MACE with colchicine therapy, with an estimated number needed to treat of 52 patients to prevent one event, which is consistent with previous reports while considering a substantially larger population.

However, it should be noted that including CLEAR lead to a meaningful increase in the studyheterogeneity, which requires careful consideration.

219 While both trials on long-term low-dose colchicine in CCS (LoDoCo and LoDoCo2) [18,30] were 220 positive for a reduction of MACE in patients in the experimental group, trials enrolling patients with 221 ACS have mostly been neutral, with the notable exception of a relatively smaller trial by Akrami and 222 colleagues.[28] While subgroup analysis showed a neutral pooled effect of colchicine in ACS patients 223 (RR 0.73, 95% CI 0.47 – 1.14), there was no statistically significant interaction between clinical 224 presentation subgroups (p = 0.60).

These findings suggest that the presence of benefit of colchicine in ACS patients cannot be excluded with the available evidence, and the treatment effect should be considered consistent across clinical presentations until definitively proven otherwise by future research.

The identification of smoking as a significant effect modifier ($\beta = 1.10$, p = 0.016) requires careful consideration. When considering the trials used for meta regression, the heterogeneity in the proportion of patients with active smoking appears to be quite significant, ranging from 4.5% and 11.8% (LoDoCo[30] and LoDoCo2[18] trials, respectively) to 40.8% (CLEAR)[22].

While providing a definite mechanistic explanation on the complex interplay between active smoking 232 and colchicine is beyond the scope of this systematic review, the finding appears biologically 233 plausible. Colchicine works by inhibiting microtubule polymerization, which reduces the activity of 234 neutrophils and other inflammatory cells.[1,35] On the other hand, active smoking is known to 235 promote chronic systemic and vascular inflammation through oxidative stress. Notably, active 236 237 smoking may lead to cellular contraction and degeneration mediated by specifically interfering with 238 microtubule function, possibly undermining a critical pharmacodynamic target in long term colchicine therapy.[36] 239

Our meta-analysis confirms the reduction in the risk of myocardial infarction and unplanned coronary 240 241 revascularization in patients in the colchicine group, by 17% and 21% respectively. On the other hand, the inclusion of the CLEAR trial[22] in the pooled analysis for individual outcomes challenges the 242 previously reported reduction in the risk of stroke. While less events were reported in the colchicine 243 group [187 (risk: 1.7%) versus 234 (risk: 2.1%)], this finding did not reach statistical significance 244 (RR 95% CI 0.50 - 1.06). Notably, the omission of CLEAR at leave-one-out analysis shows a 245 246 significant reduction of 28% for the risk of stroke (95% CI 0.58 - 0.89). Interestingly, the outcome definition of Stroke reported by the CLEAR trial[22] uniquely includes subarachnoid haemorrhage 247 and does not require imaging (CT or MRI) confirmation, potentially incorporating non-ischemic 248 249 events that could dilute the treatment effect.

Regarding the effects on mortality and the safety outcomes, the present results align with previously 250 251 published meta-analytic reports.[37] Nonetheless, the included trials were not powered to assess 252 differences in these respect and the known side-effect spectrum of colchicine and concerns regarding the long-term immunomodulatory effects warrants careful evaluation of pooled data. While our meta-253 analysis provides reassuring data regarding the safety of low-dose colchicine treatment for all the 254 255 safety outcomes, trials were not designed with appropriate power or follow-up time to thoroughly 256 assess differences in mortality. Interestingly, all trials reported a higher rate of non-cardiovascular 257 death compared to cardiovascular death, except for CLEAR,[22] despite the high cardiovascular risk of the enrolled populations. While this finding has been previously reported in published literature as 258 259 well as recent meta-analyses, [33, 34, 38] CLEAR's divergent finding warrants careful interpretation, particularly given the size and the long follow-up period. Notably, the trial's definition of 260 cardiovascular death included deaths of unknown cause, and was conducted during the COVID-19 261 262 pandemic without specific reporting of respiratory-related hospitalizations, with potential misclassification of events. 263

The Food and Drug Administration (FDA) has approved the use of low dose colchicine for secondary prevention in ischemic heart disease,[39] while the recent 2024 European Society of Cardiology (ESC) guidelines on chronic coronary syndromes[40] have upgraded its recommendation to class IIA from previous 2021 ESC guidelines on cardiovascular prevention.[41] This systematic review provides evidence that combined results of available clinical trials suggest that colchicine effectively reduces MACE in patients with acute and especially chronic coronary syndromes, even after the neutral results of the CLEAR trial.

271 *Limitations*

This meta-analysis presents several limitations. Trial differences in population and outcome definition introduced heterogeneity in the pooled estimates, and reported data did not allow for time-to-event analysis, which was planned as a secondary analysis in the prospective analysis plan. Only six of the

- 275 included trials provided clear reporting on all the pre-specified outcomes and predictors. Moreover,
- this analysis used study-level data, that carries a risk of losing important information without access
- to individual patient data.

278 Conclusions

- 279 The addition of colchicine reduces the risk of MACE, myocardial infarction and coronary
- revascularization in patients with ASCVD treated with standard of therapy, with a good safety profile.
- 281 Our findings support the use of long-term low-dose colchicine for secondary prevention of MACE in
- 282 clinical practice.

283

- Patient and public involvement: Patients and/or the public were not involved in the design, or 284
- conduct, or reporting, or dissemination plans of this research. 285
- 286 Data availability statement: Data are available on reasonable request.
- Competing interests: None declared. 287

288

289 **References**

- Imazio M, Nidorf M. Colchicine and the heart. *Eur Heart J.* 2021;42:2745–60. doi:
 10.1093/eurheartj/ehab221
- Imazio M, Agrimi C, Cescon L, *et al.* Colchicine for the treatment of the spectrum of
 cardiovascular diseases: current evidence and ongoing perspectives. *J Cardiovasc Med.* 2024;25:653–63. doi: 10.2459/JCM.00000000001647
- 295 3 Libby P, Lichtman AH, Hansson GK. Immune Effector Mechanisms Implicated in
 296 Atherosclerosis: From Mice to Humans. *Immunity*. 2013;38:1092–104. doi:
 297 10.1016/j.immuni.2013.06.009
- 298 4 Bayes-Genis A, Adler Y, De Luna AB, *et al.* Colchicine in Pericarditis. *Eur Heart J*.
 2017;38:1706–9. doi: 10.1093/eurheartj/ehx246
- 300 5 Ridker PM, Rifai N, Rose L, *et al.* Comparison of C-Reactive Protein and Low-Density
 301 Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events. *N Engl J Med.* 302 2002;347:1557–65. doi: 10.1056/NEJMoa021993
- 303 6 Ridker PM, Everett BM, Thuren T, *et al.* Antiinflammatory Therapy with Canakinumab for
 304 Atherosclerotic Disease. *N Engl J Med.* 2017;377:1119–31. doi: 10.1056/NEJMoa1707914
- Nidorf M, Thompson PL. Effect of Colchicine (0.5 mg Twice Daily) on High-Sensitivity C Reactive Protein Independent of Aspirin and Atorvastatin in Patients With Stable Coronary Artery
 Disease. *Am J Cardiol.* 2007;99:805–7. doi: 10.1016/j.amjcard.2006.10.039
- Ridker PM, Bhatt DL, Pradhan AD, *et al.* Inflammation and cholesterol as predictors of
 cardiovascular events among patients receiving statin therapy: a collaborative analysis of three
 randomised trials. *The Lancet.* 2023;401:1293–301. doi: 10.1016/S0140-6736(23)00215-5

- 311 9 Leung YY, Yao Hui LL, Kraus VB. Colchicine—Update on mechanisms of action and therapeutic
- 312 uses. Semin Arthritis Rheum. 2015;45:341–50. doi: 10.1016/j.semarthrit.2015.06.013
- 313 10 Imazio M, Bobbio M, Cecchi E, et al. Colchicine in Addition to Conventional Therapy for Acute
- 314 Pericarditis: Results of the COlchicine for acute PEricarditis (COPE) Trial. Circulation.
- 315 2005;112:2012–6. doi: 10.1161/CIRCULATIONAHA.105.542738
- I1 Imazio M, Brucato A, Cemin R, *et al.* A Randomized Trial of Colchicine for Acute Pericarditis.
 N Engl J Med. 2013;369:1522–8. doi: 10.1056/NEJMoa1208536
- 318 12 Imazio M, Bobbio M, Cecchi E, et al. Colchicine as First-Choice Therapy for Recurrent
- 319 Pericarditis: Results of the CORE (COlchicine for REcurrent pericarditis) Trial. *Arch Intern Med.*
- 320 2005;165:1987. doi: 10.1001/archinte.165.17.1987
- Imazio M, Belli R, Brucato A, *et al.* Efficacy and safety of colchicine for treatment of multiple
 recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled,
 randomised trial. *The Lancet.* 2014;383:2232–7. doi: 10.1016/S0140-6736(13)62709-9
- 14 Robinson PC, Terkeltaub R, Pillinger MH, *et al.* Consensus Statement Regarding the Efficacy
 and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease. *Am J Med.* 2022;135:32–8. doi: 10.1016/j.amjmed.2021.07.025
- 15 Imazio M. Medical therapy of pericarditis: tips and tricks for clinical practice. *J Cardiovasc Med*.
 Published Online First: 2 April 2024. doi: 10.2459/JCM.00000000001618
- Misawa T, Takahama M, Kozaki T, *et al.* Microtubule-driven spatial arrangement of mitochondria
 promotes activation of the NLRP3 inflammasome. *Nat Immunol.* 2013;14:454–60. doi:
 10.1038/ni.2550

- Tardif J-C, Kouz S, Waters DD, *et al.* Efficacy and Safety of Low-Dose Colchicine after
 Myocardial Infarction. *N Engl J Med.* 2019;381:2497–505. doi: 10.1056/NEJMoa1912388
- 18 Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease.
- 335 *N Engl J Med.* 2020;383:1838–47. doi: 10.1056/NEJMoa2021372
- 336 19 Bouabdallaoui N, Tardif J-C, Waters DD, et al. Time-to-treatment initiation of colchicine and
- 337 cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes
- 338 Trial (COLCOT). Eur Heart J. 2020;41:4092–9. doi: 10.1093/eurheartj/ehaa659
- 339 20 Nelson K, Fuster V, Ridker PM. Low-Dose Colchicine for Secondary Prevention of Coronary
- 340 Artery Disease. J Am Coll Cardiol. 2023;82:648–60. doi: 10.1016/j.jacc.2023.05.055
- 21 Kelly P, Lemmens R, Weimar C, *et al.* Long-term colchicine for the prevention of vascular
 recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial. *The*
- 343 *Lancet*. 2024;404:125–33. doi: 10.1016/S0140-6736(24)00968-1
- 22 Jolly SS, d'Entremont M-A, Lee SF, *et al.* Colchicine in Acute Myocardial Infarction. *N Engl J*
- 345 *Med.* 2024;NEJMoa2405922. doi: 10.1056/NEJMoa2405922
- Page MJ, McKenzie JE, Bossuyt PM, *et al.* The PRISMA 2020 statement: an updated guideline
 for reporting systematic reviews. *BMJ*. 2021;372:n71. doi: 10.1136/bmj.n71
- 348 24 Sterne JAC, Savović J, Page MJ, *et al.* RoB 2: a revised tool for assessing risk of bias in
 349 randomised trials. *BMJ*. 2019;366:14898. doi: 10.1136/bmj.14898
- 25 Higgins JPT, Altman DG, Gotzsche PC, *et al.* The Cochrane Collaboration's tool for assessing
 risk of bias in randomised trials. *BMJ*. 2011;343:d5928–d5928. doi: 10.1136/bmj.d5928

- 26 Psaltis PJ, Nguyen MT, Singh K, *et al.* Optical coherence tomography assessment of the impact
 of colchicine on non-culprit coronary plaque composition after myocardial infarction. *Cardiovasc Res.* 2024;cvae191. doi: 10.1093/cvr/cvae191
- 355 27 Radwan MA. Colchicine for Preserving Left Ventricular Systolic Function in Patients With
- 356 STEMI Following Successful Primary PCI: A Speckle-Tracking Echocardiography Study. *Iran*357 *Heart J.* 2024;25:84–95.
- 28 Akrami M, Izadpanah P, Bazrafshan M, et al. Effects of colchicine on major adverse cardiac
- events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-
- 360 control trial. *BMC Cardiovasc Disord*. 2021;21:583. doi: 10.1186/s12872-021-02393-9
- 29 Tong DC, Quinn S, Nasis A, *et al.* Colchicine in Patients With Acute Coronary Syndrome: The
 Australian COPS Randomized Clinical Trial. *Circulation*. 2020;142:1890–900. doi:
 10.1161/CIRCULATIONAHA.120.050771
- 30 Nidorf SM, Eikelboom JW, Budgeon CA, *et al.* Low-Dose Colchicine for Secondary Prevention
 of Cardiovascular Disease. *J Am Coll Cardiol.* 2013;61:404–10. doi: 10.1016/j.jacc.2012.10.027
- 366 31 Deftereos S, Giannopoulos G, Raisakis K, et al. Colchicine Treatment for the Prevention of Bare-
- 367 Metal Stent Restenosis in Diabetic Patients. J Am Coll Cardiol. 2013;61:1679–85. doi:
 368 10.1016/j.jacc.2013.01.055
- 369 32 Tong DC, Bloom JE, Quinn S, *et al.* Colchicine in Patients With Acute Coronary Syndrome: Two-
- 370 Year Follow-Up of the Australian COPS Randomized Clinical Trial. *Circulation*. 2021;144:1584–
- 371 6. doi: 10.1161/CIRCULATIONAHA.121.054610
- 372 33 Fiolet ATL, Opstal TSJ, Mosterd A, et al. Efficacy and safety of low-dose colchicine in patients
- 373 with coronary disease: a systematic review and meta-analysis of randomized trials. *Eur Heart J*.
- 374 2021;42:2765–75. doi: 10.1093/eurheartj/ehab115

- 375 34 Fiolet ATL, Poorthuis MHF, Opstal TSJ, *et al.* Colchicine for secondary prevention of ischaemic
 376 stroke and atherosclerotic events: a meta-analysis of randomised trials. *eClinicalMedicine*.
 377 2024;76:102835. doi: 10.1016/j.eclinm.2024.102835
- 378 35 Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline
- 379 for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart
- 380 Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.
- 381 *Circulation*. 2023;148. doi: 10.1161/CIR.00000000001168
- 382 36 Bernhard D, Csordas A, Henderson B, et al. Cigarette smoke metal-catalyzed protein oxidation
- leads to vascular endothelial cell contraction by depolymerization of microtubules. *FASEB J*.
- 384 2005;19:1096–107. doi: 10.1096/fj.04-3192com
- 385 37 Andreis A, Imazio M, Avondo S, *et al.* Adverse events of colchicine for cardiovascular diseases:
 a comprehensive meta-analysis of 14 188 patients from 21 randomized controlled trials. *J Cardiovasc Med.* 2021;22:637–44. doi: 10.2459/JCM.00000000001157
- 388 38 Opstal TSJ, Nidorf SM, Fiolet ATL, *et al.* Drivers of mortality in patients with chronic coronary
 389 disease in the low-dose colchicine 2 trial. *Int J Cardiol.* 2023;372:1–5. doi:
 390 10.1016/j.ijcard.2022.12.026
- 39 Ridker PM. The Time to Initiate Anti-Inflammatory Therapy for Patients With Chronic Coronary
 Atherosclerosis Has Arrived. *Circulation*. 2023;148:1071–3. doi:
 10.1161/CIRCULATIONAHA.123.066510
- 40 Vrints C, Andreotti F, Koskinas KC, *et al.* 2024 ESC Guidelines for the management of chronic
 coronary syndromes. *Eur Heart J.* 2024;45:3415–537. doi: 10.1093/eurheartj/ehae177
- 41 Visseren FLJ, Mach F, Smulders YM, *et al.* 2021 ESC Guidelines on cardiovascular disease
 prevention in clinical practice. *Eur Heart J.* 2021;42:3227–337. doi: 10.1093/eurheartj/ehab484

398

399 Tables

Table 1: Key features of randomized trials included in this meta-analysis 400

					Number of p	patients	Months
				Placebo-			of
Study	Year	Inclusion criteria	Intervention	controlle	Interventio	Control	follow-
				d	n group	group	up
							(median)
		Patients aged at least					
		40 years, with non-					
CONVINCE[2024	severe ischaemic	Colchicine	N	15(0	1575	24
21]	2024	stroke or high-risk	0.5 mg daily	No	1569	1373	34
		transient ischaemic					
		attack					
		Patients aged > 18					
		with STEMI and	Colchicine				
CLEAR[22]	2024	those with NSTEMI	0.5 mg daily ^a	Yes	3528	3534	36
		plus risk factors					
		10.00					
		Age 18-82 years,					
сосомо-	2024	with a coronary	Colchicine	Vec	20	21	10
ACS[26]	2024	hours of NSTEMI	0.5 mg daily	res	30	31	18
		diagnosis					
		ulagnosis					

Radwan et al.[27]	2024	STEMI patients with successful primary PCI	Colchicine 0.5 mg daily	No	100	100	6
COPS[29]	2021	Patients aged 18-85 with ACS	Colchicine 0.5 mg twice daily for 30 days, ^b followed by 0.5 mg once daily for 11 months	Yes	396	399	24 [32]‡
Akrami et al.[28]	2021	Patients aged 40-70 years, with ACS	Colchicine 0.5 mg daily	Yes	120	129	6
LoDoCo2[18]	2020	Age 35-85 years, with proven coronary artery disease (proven by either angiography or non- invasive imaging, or $CAC \ge 400$) with minimum 6-month clinical stability	Colchicine 0.5 mg daily after a 30-day run-in phase	Yes	2762	2760	29
COLCOT[17]	2019	Patients aged ≥ 18 , with MI in the 30	Colchicine 0.5 mg daily	Yes	2366	2379	22.6

		dayspriortoenrolment,withcompletionofplannedpercutaneousrevascularizationprocedures					
LoDoCo[30]	2013	Age35-85years,angiographicallyprovencoronarydiseasewithminimum6-monthclinical stability	Colchicine 0.5 mg daily	No	282	250	36
Deftereos et al.[31]	2013	Diabetic patients aged 40-80 years, undergoing PCI	Colchicine 0.5 mg twice daily	Yes	112	110	6

^a Dose changed after interim analysis showed higher-then-expected discontinuation; ^b Dose reduction 401

402 allowed according to patients' tolerance.

‡ = MACE outcome data based on pre-specified extended follow-up. 403

404 ACS = acute coronary syndrome; PCI = percutaneous coronary intervention.

Table 2. Demographics 405

Study	Year	Total number of patients	Age (Mean ± SD)	Female (%)	Diabetes (%)	Active smoker (%)	Hyperte nsion (%)	Prior CAD (%)	Prior stroke (%)
CONVINCE [21]	2024	3144	66.3 ±10	30.31	22.3	22.07	65.43	8.9	10.5
CLEAR [22]	2024	7062	60.7 ± 10.3	20.4	18.5	40.8	45.8	9 §	NA
COCOMO- ACS[26]	2024	61	62.5 ± 11.2	9.4	18.8	26.6	53.1	6.3 [§]	NA
Radwan et al.[27]	2024	200	55.3 ± 9.2	23.5	50.5	59	57	NA	NA
COPS[29]	2021	795	59.9 ±10.3	20.8	19	34.8	50.3	15.1	2
Akrami et al.[28]	2021	249	56.9 ± 7.5	30.5	23.7	40.6	44.6	8.83 [§]	3.6
LoDoCo2[1 8]	2020	5522	65.8 ± 8.6	15.3	18.3	11.8	50.9	84.4	NA
COLCOT[1 7]	2019	4745	60.6 ± 10.7	19.2	20.2	29.9	51	16.2	2.3
LoDoCo[30]	2013	532	67 ± 9.4	11.1	30.3	11.8	NA	23.5	NA
Deftereos et al.[31]	2013	222	63.6 ± 7.0	34.7	100	37.8	49	NA	NA

406

§ = Prior myocardial infarction; CAD = coronary artery disease 407

- 408 **Figures**
- 409 Figure 1. Graphical abstract: Main findings of the meta-analysis. RR = Risk Ratio; CI =
- **Confidence Interval.** 410



This meta-analysis highlights the role of prolonged therapy with low-dose colchicine in patients with atherosclerotic cardiovascular disease to reduce the risk of major adverse cardiovascular events, myocardial infarction, and coronary revascularization, while maintaining a favorable safety profile.

411

- Figure 2. Cardiovascular composite outcomes (MACE with and without coronary 412
- revascularization) in patients treated with colchicine in addition to standard of care versus 413
- 414 standard of care alone. RR = Risk Ratio, CI = Confidence Interval.

Composite of Cardiovascular Death, Myocardial Infarction, and Stroke (MACE)



Composite of MACE and Coronary Revascularization

	Colc	hicine	C	ontrol			
Study	Events	Total	Events	Total	Risk Ratio	RR	95% CI
CLEAR	322	3528	327	3534	i 📥	0.99	[0.85; 1.14]
COLCOT	131	2366	170	2379	- 12 -	0.77	[0.62; 0.97]
CONVINCE	148	1569	183	1575		0.81	[0.66; 1.00]
COPS	32	396	54	399	<u>_</u>	0.60	[0.39; 0.90]
LoDoCo	16	282	35	250		0.41	[0.23; 0.71]
LoDoCo2	187	2762	264	2760		0.71	[0.59; 0.85]
Fixed effects model		10903		10897		0.81	[0.74; 0.88]
Random effects model Heterogeneity: $J^2 = 71\%$, $T^2 = 0.0482$, $p < 0.01$				\bigcirc	0.74	[0.60; 0.91]	
0	,	,			0.5 1 2		
			Favo	ours colchicine Favours no c	olchicin	е	

415

Figure 3. Myocardial Infarction, Stroke and Coronary Revascularization in patients treated 416

with colchicine in addition to standard of care versus standard of care alone. RR = Risk Ratio, 417

CI = Confidence Interval. 418

Myocardial Infarction

	Colc	hicine	С	ontrol			
Study	Events	Total	Events	Total	Risk Ratio	RR	95% CI
CLEAR	102	3528	111	3534	#	0.92	[0.71; 1.20]
COLCOT	89	2366	98	2379	*	0.91	[0.69; 1.21]
CONVINCE	26	1569	29	1575	<u>-it</u>	0.90	[0.53; 1.52]
COPS	7	396	11	399		0.64	[0.25; 1.64]
Radwan et al.	0	100	0	100	1		
LoDoCo	10	282	18	250		0.49	[0.23; 1.05]
LoDoCo2	85	2762	117	2760		0.73	[0.55; 0.96]
COCOMO-ACS	1	30	2	31		0.52	[0.05; 5.40]
Fixed effects model		11033		11028	\diamond	0.83	[0.72; 0.96]
Random effects model	1				\$	0.83	[0.72; 0.96]
Heterogeneity: $I^2 = 0\%$, T^2	=0, p=0.6	63					
್ರ ಸೆ ಲಿ	1.12				0.1 0.5 1 2 10		
				Favo	ours colchicine Favours no co	olchicin	е

Stroke

	Colc	hicine	C	ontrol			
Study	Events	Total	Events	Total	Risk Ratio	RR	95% CI
CLEAR	50	3528	43	3534		1.16	[0.78; 1.75]
COLCOT	5	2366	19	2379		0.26	[0.10; 0.71]
CONVINCE	108	1569	136	1575		0.80	[0.63; 1.02]
COPS	4	396	7	399		0.58	[0.17; 1.95]
Radwan et al.	0	100	0	100			a 224 au
LoDoCo	2	282	4	250		0.44	[0.08; 2.40]
LoDoCo2	18	2762	25	2760		0.72	[0.39; 1.32]
COCOMO-ACS	0	30	0	31			
Fixed effects model		11033		11028	-	0.80	[0.66; 0.97]
Random effects model				\diamond	0.73	[0.50; 1.06]	
Heterogeneity: $l^2 = 45\%$, $T^2 = 0.0969$, $p = 0.11$		1					
					0.1 0.5 1 2 10)	
Favours colchicine Favours no colchicine							

Coronary Revascularization

	Colc	hicine	С	ontrol						
Study	Events	Total	Events	Total		Ri	sk Ra	tio	RR	95% CI
CLEAR	164	3528	166	3534					0.99	[0.80; 1.22]
COLCOT	132	2366	164	2379			-+		0.81	[0.65; 1.01]
CONVINCE	3	1569	7	1575			•		0.43	[0.11; 1.66]
COPS	16	396	33	399		-			0.49	[0.27; 0.87]
Deftereos et al.	4	112	5	110				-	0.79	[0.22; 2.85]
LoDoCo	13	282	22	250		8=			0.52	[0.27; 1.02]
LoDoCo2	151	2762	184	2760			+		0.82	[0.67; 1.01]
COCOMO-ACS	0	30	3	31		•		-	0.15	[0.01; 2.74]
Fixed effects model		11045		11038					0.83	[0.73; 0.93]
Random effects model							\diamond		0.79	[0.65; 0.94]
Heterogeneity: $I^2 = 30\%$, τ^2	$^{2} = 0.0208,$	p = 0.1	9							
823 X 103				C	.01	0.1	1	10	100	
				Fav	ours	colchici	ne Fa	avours no	o colchicin	e

Figure 4. Death in patients treated with colchicine in addition to standard of care versus 420

standard of care alone. RR = Risk Ratio, CI = Confidence Interval. 421

Cardiovascular Death

Colchicine C		ontrol							
Study	Events	Total	Events	Total		Risk Rati	io	RR	95% CI
CLEAR	117	3528	113	3534				1.04	[0.80; 1.34]
COLCOT	20	2366	24	2379		-		0.84	[0.46; 1.51]
CONVINCE	16	1569	17	1575		+		0.94	[0.48; 1.86]
COPS	4	396	2	399		-+		2.02	[0.37; 10.94]
Deftereos et al.	1	112	1	110				0.98	[0.06; 15.51]
Radwan et al.	0	100	0	100					
LoDoCo	0	282	4	250				0.10	[0.01; 1.82]
LoDoCo2	20	2762	25	2760		-		0.80	[0.45; 1.44]
COCOMO-ACS	0	30	0	31					
Fixed effects model		11145		11138		↓		0.96	[0.78; 1.17]
Random effects model						\$		0.97	[0.79; 1.19]
Heterogeneity: $I^2 = 0\%$, $T^2 = 0$, $p = 0.68$						I			
					0.01 0.1	1	10	100	
Favours colchicine Favours no colchicine									

Non-Cardiovascular Death

	Cold	hicine	C	Control			
Study	Events	Total I	Events	Total	Risk Ratio	RR	95% CI
CLEAR	45	3528	66	3534	<u>k</u>	0.68	[0.47; 0.99]
COLCOT	23	2366	20	2379		1.16	[0.64; 2.10]
CONVINCE	45	1569	41	1575	- <u>-</u>	1.10	[0.73; 1.67]
COPS	5	396	2	399		— 2.52	[0.49; 12.91]
LoDoCo	5	282	5	250		0.89	[0.26; 3.03]
LoDoCo2	53	2762	35	2760	-	1.51	[0.99; 2.31]
Fixed effects model		10903		10897	\diamond	1.04	[0.84; 1.28]
Random effects mode	el				\diamond	1.07	[0.80; 1.42]
Heterogeneity: $I^2 = 46\%$,	т ² = 0.0428,	p = 0.10				1	
					0.1 0.5 1 2 1	0	
				Fav	ours colchicine Favours no c	olchicin	е